​

Adaptive Bio (ADPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ADPT Stock Forecast

Adaptive Bio (ADPT) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $21.25, with a high of $22.00 and a low of $21.00. This represents a 70.68% increase from the last price of $12.45.

- $5 $10 $15 $20 $25 High: $22 Avg: $21.25 Low: $21 Last Closed Price: $12.45

ADPT Stock Rating

Adaptive Bio stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (64.71%), 4 Hold (23.53%), 2 Sell (11.76%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 2 4 11 Strong Sell Sell Hold Buy Strong Buy

ADPT Price Target Upside V Benchmarks

TypeNameUpside
StockAdaptive Bio70.68%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-36
Avg Price Target-$21.33$20.83
Last Closing Price$12.45$12.45$12.45
Upside/Downside-71.33%67.31%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26251--8
Feb, 26251--8
Jan, 26251--8
Dec, 25251--8
Nov, 25251--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 06, 2026BTIG$22.00$16.4733.58%76.71%
Feb 06, 2026Sebastian SandlerPiper Sandler$21.00$16.4727.50%68.67%
Jan 26, 2026Guggenheim$21.00$18.9111.05%68.67%
Dec 01, 2025Kallum TitchmarshMorgan Stanley$21.00$18.8411.46%68.67%
Oct 15, 2025Piper Sandler$20.00$16.2822.85%60.64%
Sep 30, 2025Guggenheim$20.00$13.4648.59%60.64%
Apr 04, 2024Mark MassaroBTIG$5.00$2.6886.57%-59.84%
Dec 21, 2022David WestenbergPiper Sandler$14.00$7.0997.46%12.45%
Aug 17, 2022David WestenbergPiper Sandler$12.00$11.553.90%-3.61%
Jun 13, 2022David WestenbergPiper Sandler$7.50$6.977.60%-39.76%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 06, 2026Cowen & Co.BuyBuyhold
Feb 06, 2026BTIGBuyBuyhold
Jan 26, 2026GuggenheimBuyBuyhold
Jan 13, 2026Piper SandlerOverweightOverweighthold
Jan 07, 2026Cowen & Co.BuyBuyhold
Oct 15, 2025Piper SandlerOverweightOverweighthold
Sep 30, 2025GuggenheimBuyinitialise
Jun 18, 2025Craig-HallumBuyinitialise
May 06, 2025Piper SandlerOverweightOverweighthold
Dec 18, 2024BTIGBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-1.46$-1.00$-1.56$-1.08$-0.39-
Avg Forecast$-1.49$-1.47$-1.41$-1.12$-0.94$-0.67
High Forecast$-1.40$-1.41$-1.40$-1.11$-0.83$-0.52
Low Forecast$-1.56$-1.53$-1.44$-1.12$-1.03$-0.89
Surprise %-2.01%-31.97%10.64%-3.57%-58.51%-

Revenue Forecast

$100M $140M $180M $220M $260M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$154.34M$185.31M$170.28M$178.96M$276.98M-
Avg Forecast$152.83M$185.10M$172.93M$177.62M$210.66M$264.13M
High Forecast$158.09M$190.53M$183.72M$179.32M$216.88M$265.49M
Low Forecast$145.20M$179.67M$168.57M$174.90M$204.25M$262.77M
Surprise %0.99%0.11%-1.54%0.75%31.48%-

Net Income Forecast

$-350M $-290M $-230M $-170M $-110M $-50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-207.28M$-200.19M$-225.25M$-159.49M$-59.50M-
Avg Forecast$-232.25M$-258.20M$-225.25M$-160.99M$-141.48M$-100.85M
High Forecast$-185.80M$-206.56M$-180.20M$-159.55M$-120.32M$-74.91M
Low Forecast$-278.70M$-309.84M$-270.30M$-162.43M$-148.21M$-128.21M
Surprise %-10.75%-22.47%--0.93%-57.94%-

ADPT Forecast FAQ

Is Adaptive Bio stock a buy?

Adaptive Bio stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 4 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Adaptive Bio is a favorable investment for most analysts.

What is Adaptive Bio's price target?

Adaptive Bio's price target, set by 17 Wall Street analysts, averages $21.25 over the next 12 months. The price target range spans from $21 at the low end to $22 at the high end, suggesting a potential 70.68% change from the previous closing price of $12.45.

How does Adaptive Bio stock forecast compare to its benchmarks?

Adaptive Bio's stock forecast shows a 70.68% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Adaptive Bio over the past three months?

  • March 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 25.00% Strong Buy, 62.50% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Adaptive Bio’s EPS forecast?

Adaptive Bio's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.67, marking a 71.79% increase from the reported $-0.39 in 2025..

What is Adaptive Bio’s revenue forecast?

Adaptive Bio's average annual revenue forecast for its fiscal year ending in December 2026 is $264.13M, reflecting a -4.64% decrease from the reported $276.98M in 2025.

What is Adaptive Bio’s net income forecast?

Adaptive Bio's net income forecast for the fiscal year ending in December 2026 stands at $-101M, representing an 69.50% increase from the reported $-59.499M in 2025.